Publications by Håvard Midgard

24 publications found

Publications 2021

  1. Dalgard O, Midgard H, Kielland KB (2021)
    Hepatitis C in Iceland: a milestone for global elimination
    Lancet Gastroenterol Hepatol, 6 (8), 599-600
    DOI 10.1016/S2468-1253(21)00182-5, PubMed 34171268
  2. Fadnes LT, Aas CF, Vold JH, Leiva RA, Ohldieck C, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2021)
    Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
    PLoS Med, 18 (6), e1003653
    DOI 10.1371/journal.pmed.1003653, PubMed 34061883
  3. Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O (2021)
    Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
    Int J Drug Policy, 103165 (in press)
    DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182

Publications 2020

  1. Haukeland JW, Småstuen MC, Pålsdatter PP, Ismail M, Konopski Z, Jørgensen KK, Lannerstedt H, Midgard H (2020)
    Effect of gender on mortality and causes of death in cirrhotic patients with gastroesophageal varices. A retrospective study in Norway
    PLoS One, 15 (3), e0230263
    DOI 10.1371/journal.pone.0230263, PubMed 32163489
  2. Midgard H, Finbråten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjørnestad R, Dalgard O (2020)
    Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs
    Trials, 21 (1), 524
    DOI 10.1186/s13063-020-04434-8, PubMed 32539853

Publications 2019

  1. Fadnes LT, Aas CF, Vold JH, Ohldieck C, Leiva RA, Chalabianloo F, Skurtveit S, Lygren OJ, Dalgård O, Vickerman P, Midgard H, Løberg EM, Johansson KA, INTRO-HCV Study Group (2019)
    Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
    BMC Infect Dis, 19 (1), 943
    DOI 10.1186/s12879-019-4598-7, PubMed 31703669
  2. Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J (2019)
    Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis
    J Hepatol, 72 (4), 643-657
    DOI 10.1016/j.jhep.2019.11.012, PubMed 31785345
  3. Øvrehus ALH, Midgard H (2019)
    How can we achieve WHO's elimination target for hepatitis C incidence?
    Lancet Gastroenterol Hepatol, 4 (6), 415-417
    DOI 10.1016/S2468-1253(19)30120-7, PubMed 30981687
  4. Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV (2019)
    The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination
    Clin Infect Dis, 69 (12), 2218-2227
    DOI 10.1093/cid/ciz714, PubMed 31352481
  5. Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O (2019)
    The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients
    Scand J Gastroenterol, 54 (9), 1172-1175
    DOI 10.1080/00365521.2019.1643403, PubMed 31479286

Publications 2018

  1. Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J, International Network on Hepatitis in Substance Users (INHSU) (2018)
    Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework
    Liver Int, 39 (1), 20-30
    DOI 10.1111/liv.13949, PubMed 30157316
  2. Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Matičič M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M (2018)
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
    J Hepatol, 68 (3), 402-411
    DOI 10.1016/j.jhep.2017.10.010, PubMed 29080808
  3. Midgard H (2018)
    Hepatitis C in drug addicts
    Tidsskr. Nor. Laegeforen., 138 (13), 1243
  4. Midgard H, Kielland KB, Dalgard O (2018)
    Elimination of Hepatitis C is possible
    Tidsskr. Nor. Laegeforen., 138 (7), 630-633
  5. Midgard H, Kielland KB, Dalgard O (2018)
    [Elimination of hepatitis C is possible]
    Tidsskr Nor Laegeforen, 138 (7)
    DOI 10.4045/tidsskr.18.0099, PubMed 29663789

Publications 2017

  1. Bjøro B, Dalgard O, Midgard H, Verbaan H, Småstuen MC, Rustøen T (2017)
    Increased hope following successful treatment for hepatitis C infection
    J Adv Nurs, 74 (3), 724-733
    DOI 10.1111/jan.13487, PubMed 29082540
  2. Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J, ACTIVATE Study Group (2017)
    Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
    BMC Infect Dis, 17 (1), 420
    DOI 10.1186/s12879-017-2517-3, PubMed 28610605
  3. Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I et al. (2017)
    Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
    Int J Drug Policy, 47, 51-60
    DOI 10.1016/j.drugpo.2017.05.019, PubMed 28683982
  4. Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ, ACTIVATE Study Group (2017)
    Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
    Int J Drug Policy, 47, 177-186
    DOI 10.1016/j.drugpo.2017.05.020, PubMed 28624134
  5. Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J, ACTIVATE Study Group (2017)
    Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
    Int J Drug Policy, 47, 230-238
    DOI 10.1016/j.drugpo.2017.05.040, PubMed 28633998

Publications 2016

  1. Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O (2016)
    Hepatitis C reinfection after sustained virological response
    J Hepatol, 64 (5), 1020-1026
    DOI 10.1016/j.jhep.2016.01.001, PubMed 26780289
  2. Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O (2016)
    Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
    PLoS One, 11 (11), e0166451
    DOI 10.1371/journal.pone.0166451, PubMed 27846264
  3. Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, Dalgard O (2016)
    HCV epidemiology in high-risk groups and the risk of reinfection
    J Hepatol, 65 (1 Suppl), S33-S45
    DOI 10.1016/j.jhep.2016.07.012, PubMed 27641987

Publications 2010

  1. Midgard H, Bang C, Raknerud N, Dalgard O (2010)
    Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
    Scand J Gastroenterol, 45 (12), 1503-8
    DOI 10.3109/00365521.2010.510571, PubMed 20698740

 
Page visits: 69